Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample by Marvella E Ford et al.
Ford et al. SpringerPlus  (2015) 4:411 
DOI 10.1186/s40064-015-1208-z
SHORT REPORT
Evaluating the reliability of the Attitudes 
to Randomized Trial Questionnaire (ARTQ)  
in a predominantly African American sample
Marvella E Ford1,5*, Wei Wei5, Leslie A Moore2, Dana R Burshell3, Kimberly Cannady1,5, Franshawn Mack4, 
Nnadozie Ezerioha2, Kelley Ercole6 and Elizabeth Garrett‑Mayer5
Abstract 
Purpose: To evaluate the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in measuring percep‑
tions of cancer clinical trials in a predominantly African American (AA) sample in South Carolina (SC).
Methods: Principal Component Analysis (PCA) and Cronbach’s alpha estimates were used to assess the reliability of 
the ARTQ in a convenience sample of 315 participants (81.4 % AA) who were recruited from 2008 to 2013, and who 
live in eleven different counties in South Carolina with high rates of racial disparities in cancer mortality rates.
Results: Slightly more than half of the 315 participants had at least a college education (77.9 %), 84.8 % were female, 
and 53.1 % had an annual income of $40,000 or more. In this study, PCA confirmed that the ARTQ is unidimensional. 
Cronbach’s alpha for the ARTQ was 0.86.
Conclusion: The ARTQ displayed strong evidence of high statistical reliability. This analysis has great implications 
for future research because it represents the first test of reliability of the ARTQ in a predominantly African American 
sample and lays the groundwork for use of the ARTQ in future studies in diverse populations.
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Background
Cancer is the second leading cause of death in the United 
States where it accounts for more than one million deaths 
per year. For the majority of cancer types, African Ameri-
cans have the highest cancer mortality rate of any other 
racial or ethnic group in the United States (Seigel et  al. 
2014). For example, in breast cancer, African American 
women have a 28  % higher death rate as compared to 
European Americans (EA) despite a 13  % lower rate of 
developing breast cancer (Harris et  al. 2003). In South 
Carolina (SC), rates of cancer related deaths are among 
the highest in the nation, particularly among African 
Americans (Seigel et  al. 2014). A possible contributor 
toward these disparities could be negative perceptions 
of cancer and cancer clinical trials (Fleissig et  al. 2001; 
Ramirez et  al. 2005; Seigel et  al. 2014; Ford et  al. 2012; 
Langford et al. 2010). Testing the reliability of the ARTQ 
in African American populations will indicate if the 
ARTQ is an effective tool for insight into this particular 
population’s ideas about clinical trials and willingness to 
participate.
Conceptual framework
Previous studies show that members of African Ameri-
can (AA) communities may require additional knowledge 
about cancer screening, prevention, early detection, and 
treatment. Low levels of knowledge are associated with 
low self-efficacy and low rates of participation in prostate, 
breast and cervical cancer screening (Barber et al. 1998; 
Glick et  al. 2012). For example, many AA men report 
that clinicians do not communicate effectively with 
them about prostate cancer screening (Sellers and Ross 
2003). Lack of knowledge precludes patients’ feelings of 
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self-efficacy to actively engage in shared decision making 
about screening with their clinicians. Therefore, as can-
cer knowledge increases, participants’ confidence in their 
ability to effectively communicate with their clinicians 
about cancer would be expected to increase commensu-
rately (Sellers and Ross 2003).
The need to expand the knowledge base of cancer clini-
cal trials among diverse community members is under-
scored by Ford et  al. (2012) who reviewed sixty-five 
studies focusing on recruitment of racially and ethni-
cally diverse participants to cancer clinical trials. Lack of 
education regarding cancer clinical trials was the most 
frequently reported barrier to participation (Ford et  al. 
2012). Similarly, Langford et  al. (2010) reports that lack 
of knowledge about clinical trials, and subsequent nega-
tive perceptions of them, are formidable barriers to the 
participation of diverse populations in trials.
Thus, as shown in Fig. 1, lack of knowledge about tri-
als can lead to negative perceptions of them, which in 
turn has a negative impact on trial participation. Unfor-
tunately, negative perceptions of cancer clinical trials 
based on lack of knowledge can negatively impact trial 
recruitment in the very populations that could most 
benefit from the scientific knowledge gained through 
their participation (Fisher and Kalbaugh 2001). Fallow-
field et al. (1998) argue that recruitment difficulties often 
arise from potential participants’ lack of understanding 
of terms such as “randomization.” Misperceptions in the 
randomization process (i.e., for participants with cancer, 
the minimum level of care received is the best available 
current treatment rather than placebo) can also lead to 
suspicion on the part of potential participants about the 
ethical nature of the research (Fleissig et  al. 2001; Ford 
et al. 2008).
Rationale for testing the reliability of the ARTQ in a 
predominantly African American sample
While greater participation in cancer clinical trials 
among AAs could help to reduce this disparity, nega-
tive perceptions of trials may play a role in negatively 
impacting trial participation in this population. The 
objective of this study is to evaluate the reliability of the 
Attitudes to Randomized Trial Questionnaire (ARTQ) 
in assessing perceptions of cancer clinical trials in pre-
dominantly AA populations in South Carolina (SC). The 
ARTQ was developed in Europe and has not yet been 
tested for use in an AA sample (Fallowfield et al. 1998).
Before clinical trial perceptions among AAs can be 
improved, investigators must first understand the atti-
tudes of the AA population towards these trials. However, 
in order for health disparities research to be conducted in 
a meaningful manner, it is important to determine first 
whether measures developed among non-minority popu-
lations perform in the same way when applied to minor-
ity populations.
The results of the seven-question survey called the 
Attitudes to Randomized Trial Questionnaire (ARTQ) 
developed and tested in Europe, suggest that most 
patients have positive perceptions of clinical trials and 
were willing to consider trial participation (Fallowfield 
et al. 1998). Analysis demonstrated that this instrument 
was reliable in a European population in evaluating the 
perceptions of study participants towards clinical tri-
als (Fallowfield et al. 1998; Jenkins et al. 2010). This tool 
may be useful in assessing perceptions of clinical trials in 
the AA population and has been used in previous studies 
(Ford et al. 2012). However, the reliability of this instru-
ment has never before been tested in a US or an AA 
sample and its applicability in this population is unclear. 
Kidder noted that instruments tested and developed in 
one type of population may show high reported reliabil-
ity in that population but low reliability when applied to 
another population (Kidder et  al. 1986; Kimberlin and 
Winterstein 2008). Therefore, before the ARTQ is widely 
used in AA populations in future studies, it is important 
to confirm the reliability of this instrument in an AA 
population, and compare it with reliability results of the 
instrument in EA populations (Kimberlin and Winter-
stein 2008).
The factorial structures of health measures may vary 
across racial Groups (Seigel et al. 2014). It has been noted 
that self-reports of health by older AA and Caucasian 
adults do not merely reflect clinical status or objective 
health but also the influences of cultural and social fac-
tors (Ford et  al. 2004). For example, Gibson used latent 
variable confirmatory factor analysis to examine racial 
differences in the structure and measurement of self-
reports of health widely used in studies involving older 
adults (Gibson 1991).
As Gibson (1991) concluded, additional factors unique 
to each racial group that influence subjective interpreta-
tion of health state could be modeled; supporting that 











Fig. 1 Conceptual framework of perceptions of clinical trials.
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AAs and Caucasians and comparing the results may 
reflect not only a true racial difference but also differ-
ences in the reliability and validity of the measurement 
instrument or its underlying construct(s) for the two 
groups (Gibson 1991; Kimberlin and Winterstein 2008). 
Therefore, the objective of this study was to evaluate the 
reliability of the ARTQ in a sample of AAs who were 
recruited at multiple Train the Trainer intervention sites 
in South Carolina.
Methods
Study sample and rationale for site selection
The clinical trial education program was part of a larger 
4-h evidence-based cancer education program in which 
a 3-h component focused on general cancer knowledge, a 
30-min component focused specifically on prostate can-
cer knowledge, and a 30-min component focused on can-
cer clinical trials knowledge. A pretest/posttest design 
was also used to determine the effectiveness of the pro-
gram. Only pre-test data were used in this analysis.
The cancer clinical trial education program was con-
ducted at ten sites in eleven different counties repre-
senting several different geographic regions of the state 
(Fig. 2). These eleven counties (and sites) include Berke-
ley (Varnertown Indian Community), Georgetown 
(Georgetown), Charleston (Charleston and Johns Island), 
Greenville (Greenville), Orangeburg (both Orangeburg 
sites), Richland (Columbia), Bamberg (Denmark), Flor-
ence (Florence), Darlington (Darlington), Hampton 
(Yemassee), and Williamsburg (Kingstree). The study 
included a convenience sample of participants in com-
munities with high racial disparities in cancer mor-
tality rates. The counties where the intervention was 
conducted seem to be clustered in certain areas because 
of the word-of-mouth response to the program. Because 
it was conducted in certain counties, representatives of 
neighboring counties have asked for the program to be 
conducted in their counties as well.
As shown in Table 1, which describes 2007 cancer mor-
tality rates for AAs versus EAs, the rates are significantly 
higher for AAs. In South Carolina, the cancer mortal-
ity rate for AAs is 223.1, compared with 183.2 for EAs. 
Table 2 describes the demographic characteristics of the 
counties where the cancer education program was con-
ducted. As may be seen, the majority of the counties 
have median household incomes and per capita incomes 
below that of the United States or even of South Caro-
lina as a whole. As will be described (see section enti-
tled “community engagement activities conducted in the 
study”), a variety of community engagement strategies 
were employed to recruit participants in these identified 
communities.
Fig. 2 Program sites in South Carolina.
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In South Carolina, racial differences are seen in cancer 
related behaviors. These differences could contribute to 
the disparities in cancer mortality rates that are shown in 
Table 1. For example, in South Carolina in 2009, 20.6 % 
of EAs smoked, versus 21.4 % of AAs; 64.2 % of EAs were 
overweight/obese, compared with 75.7 % of AAs; among 
the non-elderly population in the state, only 47 % of AAs 
had employer-sponsored health insurance coverage, 
compared with 64 % of EAs; and among the non-elderly 
population in the state, 46 % of EAs versus 49 % of AAs 
had Medicaid coverage (Neighbors et  al. 2003). These 
data show that AAs are more likely than EAs to have 
higher rates of risk factors for cancer and at the same 
time, lower rates of access to care (Prevention 2011; Reid 
et al. 2010).
  • Berkeley (Varnertown Indian Community)
  • Georgetown (3 in Georgetown)
  • Charleston (2 in Charleston and 1 in Johns Island)
  • Greenville (Greenville)
  • Orangeburg (2 in Orangeburg and 1 in Santee)
  • Richland (Columbia)
  • Bamberg (Denmark)
  • Florence (Florence)
  • Darlington (Darlington)
  • Hampton (Yemassee)
  • Williamsburg (Kingstree)
Measures
The ARTQ, a seven-item instrument developed by Fal-
lowfield et  al. was used to assess perceptions of cancer 
clinical trials (Fallowfield et  al. 1998). Table  3 lists the 
instrument questions. Question 1 inquires if patients/
survey participants should be asked to take part in medi-
cal research. Questions 2 and 3 inquire if the survey 
participant would consider enrolling in clinical research 
comparing treatments. Question 3 explores the partici-
pant’s response if the study were a treatment chosen at 
random. In Questions 4–6, participants are asked to 
read three statements providing more information about 
research studies: (1) both treatments were completely 
suitable for the participant (Question 4); (2) a study par-
ticipant could leave the study if the treatment did not 
suit him or her (Question 5); and (3) the doctor would 
explain both treatments prior to the participant being 
randomized (Question 6). Participants are then asked 
if knowing this additional information would encour-
age them to take part in a clinical trial. Question 7 asks 
whether knowing the extra information from the three 
previous statements would affect their willingness to 
participate in a clinical trial (Fallowfield et al. 1998). The 
ARTQ questions were read to the group of participants, 
and individuals recorded their responses, “Yes,” “No,” 
or “Do Not Know,” on paper copies which were subse-
quently de-identified. Additional survey items assessed 
general demographic characteristics of participants, 
including Hispanic ethnicity, race, highest level of educa-
tion completed, marital status, household income, age, 
and gender.
Statistical analysis
The survey data were double-entered into SPSS 21 
and were compared for verification of data entry. Data 
were exported to a comma-separated format and ana-
lyzed using the R statistical package (R version 2.3.0). 
Responses were coded as “Yes,” “No,” and “Don’t Know.”
Two approaches were considered for handling the 
three-level response variable. The first approach treated 
response as a binary variable by coding “don’t know” as 
missing, whereas the second approach took response as a 
categorical variable with three levels. Our primary infer-
ences are based on treating “Don’t Know” as “missing.” 
The latter approach was used as a sensitivity analysis to 
evaluate how sensitive our inferences were to the differ-
ent approaches for coding responses. Using the recoded 
data, tetrachoric correlations were calculated, which con-
vert a measure of association (the odds ratio) between 
two binary measures to a correlation (−1 to 1) scale.
Principal components analysis was then applied to the 
correlation matrix. The eigenvalues from the principal 
components analysis were evaluated to determine the 
dimensionality of the scale. After concluding that unidi-
mensionality of the items was appropriate, Cronbach’s 
alpha was used to measure the internal consistency reli-
ability of the items. Several approaches were considered 
for handling the three-level variable, including combining 
Table 1 Age-adjusted cancer mortality rates for the counties where the program was conducted
Source: Division of Biostatistics and Health GIS, PHSIS, SC DHEC; 2009 Cancer Mortality data using age adjusted rates from the 2000 US Standard Population.


























European American 167.9 n/aa 158.3 217.1 171.1 156.4 187.8 165.1 209.5 155.9 156.9 182.9
African American 210.9 275.3 239.3 227.1 182.3 229.6 228.2 180.8 259.6 250.8 253.5 208.7
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“Don’t Know” with “No”, recoding “Don’t Know” as miss-
ing, and using a polychoric correlation. Our primary 
inferences are based on replacing “Don’t Know” with 
“No.”
Results
Since our analysis only focused on the binary Yes/
No responses to the ARTQ items, the “Don’t Know” 
responses were coded as missing in the calculation of the 
Cronbach’s alpha.
Table  4 shows the demographic characteristics of all 
participants (n = 315). Among those who reported data 
for each category the majority were AA (81.4  %) and 
female (84.8 %). Slightly more than 60 % of participants 
had at least a college degree. About half were either wid-
owed, divorced, separated, or never married (53.3 %), and 
almost half had an annual household income of more 
than $40,000 (53.4 %).
Table 5 shows a comparison of the study demographics 
to South Carolina’s demographics using the 2010 South 
Carolina Census data (Bureau 2010, 2015).
Figure  3, made with the R 3.1.2. Software shows the 
proportion of participants who responded Yes/No/Don’t 
Know for the seven items in the ARTQ. The proportion 
of Yes is higher in all questions (≥66 %) compared to No/
Don’t know with the exception of question 3 (Y = 32 %, 
N = 35 %, DK = 33 %).
Psychometric properties of the ARTQ
There was strong evidence of unidimensionality: the first 
eigenvalue in PCA was 4.5, the second was 0.76. This can 
be interpreted to mean that 64 % (4.5/7) of the variance 
in the seven items is explained by a combined composite 
score. As a result, it is appropriate to assume the items 
are measuring the same construct and to evaluate the 
internal consistency reliability of the items. This was 
done by using Cronbach’s alpha, which was 0.86, indicat-
ing high reliability. Sensitivity analysis was implemented 
and results were similar, suggesting the handling of “don’t 
know” responses had little effect on the reliability.
Limitations
It is unclear whether similar responses would have been 
seen in a sample that had a greater proportion of men. 
However, in our previous study focusing on recruitment 
of AA men to a cancer clinical trial, female spouses or 
partners were found to serve as “gatekeepers” in terms 
of access to the male study participants. The prior study 
also showed that women transmitted health information 
to the men in their lives (Ford et al. 2001, 2008; Griffith 
et  al. 2012). Therefore, in the present study, although 
efforts were made to include men by publicizing the can-
cer education sessions in each area with male-dominated 
organizations such as fraternities, masonic orders, and 
ministerial alliances, the investigators felt confident that 
the women who participated in the sessions would share 
the information with their husbands, sons, nephews, and 
others.
Discussion
The results of this study show that the ARTQ is a reli-
able instrument in the AA sample and could be used to 
assess perceptions of cancer clinical trials among AAs 
in future studies. The ARTQ showed high percent-
ages of Yes responses to all items with the exception 
of Question 3. This shows that most participants are 
Table 3 Seven-item Attitudes to Randomized Trials Questionnaire (ARTQ)
Previous validation showed that the ARTQ scores predicted trial participation [12]
The ARTQ is interviewer administered. Responses include Yes, No, Do Not Know (DK)
Perceptions of clinical trials
 1. Do you think that patients should be asked to take part in medical research?
 2. Suppose that you were asked to take part in a research study comparing two treatments, both of which were suitable for your illness. Would you be 
prepared to take part in a study comparing different treatments?
 3. Usually the only scientific way to compare one treatment with another is for the choice between the two to be made randomly, rather like tossing a 
coin. Would you be prepared to take part in a study where treatment was chosen at random?
 4. If you answered “No” or “DK” to Question 3, we would now like to ask you a bit more about this. In a randomized study a choice would be made 
between two treatments, either of which would be suitable for you. Your doctor and experts in the field do not know for sure if one treatment is 
better than the other, or if they are both the same. That’s why they want to do the study. Would knowing that encourage you to take part?
 5. In a random choice study, if the treatment you were receiving did not suit you for any reason you could leave the study. Your doctor would then 
give you whatever treatment might be appropriate for you. Would that encourage you to take part?
 6. Before you agreed to enter a random choice study the doctor would tell you all about the two treatments being compared, before you were allo‑
cated to one or the other. Would that encourage you to take part?
Intention/willingness to participate in a clinical trial
 7. If you knew all the following things were taken in account, would you change your mind and agree to take part in the study? Both treatments were 
completely suitable. You could leave the study if the treatment did not suit you. There is plenty of information before the random choice was made
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generally are willing participants in clinical trials if they 
are approached.
An important finding emerged related to the dimen-
sionality of the ARTQ. Previous studies with predomi-
nantly EA samples showed that the ARTQ exhibited 
two factors: perceptions of clinical trials and willingness 
to participate in a clinical trial. However, in the present 
study, the results showed that the ARTQ exhibited unidi-
mensionality, with only one factor—perceptions of clini-
cal trials. Our previously published data showed that for 
each of the seven items on the ARTQ, responses changed 
in a more positive direction from pre-intervention to 
post-intervention (p < 0.01) (M. Ford et al. 2012). Thus, 
the intervention resulted in more favorable perceptions 
and greater willingness to participate in a trial if offered. 
However, the psychometric analyses of the present study 
showed that willingness to participate was not a separate 
factor on the scale in this predominantly AA sample.
No other studies reported in the literature have evalu-
ated the ARTQ in assessing perceptions of trials among 
AAs, as the majority of studies using the ARTQ have 
been conducted in Europe. As such, the present study 
makes an important contribution to the research lit-
erature. This contribution is the development of cultur-
ally equivalent measures and signifies a step forward in 
the accurate assessment of health, health determinants 
and outcomes in the context of multicultural research, 
thus potentially contributing to the alleviation of health 
disparities.
While prior published results indicated the ARTQ 
showed high reliability in EA populations, its reliability 
needed to be tested in an AA population. Substantial dif-
ferences related to health outcomes have been observed 
across different ethnic/racial groups (Ramirez et  al. 
2005). However, it is uncertain whether these observed 
differences reflect true differences, or whether they 





Racea (n = 296)
 African American 241 (81.4)
 Native American/Alaskan native 15 (5.1)
 European American 40 (13.5)
Gendera (n = 211)
 Male 32 (15.2)
 Female 179 (84.8)
Hispanica (n = 298)
 Yes 6 (2.0)
 No 292 (98.0)
Agea (n = 297)
 <50 137 (46.1)
 51–64 107 (36.0)
 65–75 45 (15.1)
 76+ 8 (2.7)
Education levela (n = 298)
 <8 years 4 (1.3)
 8–11 11 (3.7)
 12 years or HS completion 31 (10.4)
 Post‑HS other than college 20 (6.7)
 Some college 51 (17.1)
 College graduate 100 (33.6)
 Postgraduate 81 (27.2)
Marital statusa (n = 297)
 Married or living as married 139 (46.8)
 Widowed 24 (8.1)
 Divorced 48 (16.2)
 Separated 9 (3.0)
 Never married 77 (26.0)
Incomea (n = 286)
 $0–$19,999 66 (23.1)
 $20,000–$39,999 67 (23.4)
 $40,000–$59,999 61 (21.3)
 $60,000–$79,999 43 (15.0)
 $80,000+ 49 (17.1)
Table 5 Comparison of  study participant demograph-
ics (N  =  315) to  South Carolina (SC) demographics 
(N = 4,625,364)
South Carolina 2010 census data.
HS high school.
a Missing data.
Variable Study % SC %
Racea (n = 296)
 African American 81.4 28.0
 Native American/Alaskan native 5.1 0.5
 European American 13.5 68.4
Gendera (n = 211)
 Male 15.2 48.6
 Female 84.8 51.4
Hispanica (n = 298)
 Yes 2.0 5.3
Agea (n = 297)
 ≥65 17.8 14.7
Education levela (n = 298)
 College graduate 60.8 24.2
Marital statusa (n = 297)
 Married or living as married 46.8 59.0
Income∆ (n = 286) see note below
 The median income of the study participants fell between $40,000 and 
$59,000. The median income in SC is $44,587
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merely reflect cultural bias in the measures (Liang et al. 
1987; Neighbors et al. 2003; Ramirez et al. 2005). The pre-
sumption of social or cultural homogeneity exacerbates 
inaccurate cultural stereotypes, can lead to misleading 
conclusions in comparing prevalence of disorders, and 
can hinder the delivery of quality health care to different 
racial and ethnic groups.
In the context of cross-cultural comparison, an impor-
tant factor is consideration of the population of origin for 
instrument development, and whether the instrument 
has been tested for use in other populations. Instru-
ments that are not validated with respect to a particular 
racial or ethnic group are likely to carry different psycho-
metric properties than is the one originally developed. 
For example, Fillenbaum et  al. examined seven cogni-
tive screening or neuropsychological tests in relation to 
clinical diagnosis (Fillenbaum et  al. 1990). The authors 
reported that most measures, when adjusted for race and 
education, had lower specificities for AAs than for whites 
(Fillenbaum et al. 1990).
Patients may decline entry into randomized clini-
cal trials because of uncertainty about personal ben-
efit (Llewellyn-Thomas et  al. 1991), concerns as to 
whether or not the best available treatment would be 
given (although it has been shown that trial participa-
tion leads to better outcomes and overestimation of the 
likely therapeutic benefits of standard therapy) (Shel-
don et  al. 1993). Poor understanding about the value of 
clinical trials specifically and experiments in medicine 
in general, produces suspicion and confusion among the 
general population. This may help to explain why the pro-
portions of Yes/No/Don’t Know responses to ARTQ Item 
3 were so close together. It is important to note the eth-
nicity of the study’s participants. The percentages of AAs 
and Native Americans/Alaskan Natives in the study are 
substantially higher than the state population percentage. 
In South Carolina the state percentage of AAs is 28  %, 
whereas in study sample it was 81.4 %. The state percent-
age of Native Americans/Alaskan Natives is 0.5 % and in 
the study sample it was 5.1 %. These data reflect the par-
ticipants’ willingness to participate in the intervention at 
rates higher than their representation on the state level.
It is possible that the outcomes of the Train the Trainer 
program are attributable to the relatively high level of 
education of the participants. According to the 2010 
U.S. Census Bureau estimates, only 24.2 % of the South 
Carolina population over the age of 25 has completed 
their bachelor’s degree. In the present study, 33.6  % of 
the participants had obtained a college diploma and an 
additional 27.2 % had completed postgraduate education. 
Thus, the participants in this study were more highly 
educated than the general population of South Carolina. 
However, the incorporation of the “Train the Trainer” 
approach means that the participants are now equipped 
to administer the intervention in their own communities 
to those with lower levels of education, who might not 
Fig. 3 Proportion of participants who responded Yes/No/Don’t Know for the seven items in the attitudes to randomized trials questionnaire.
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participate in a university-sponsored intervention but 
who may participate in a more grassroots-level interven-
tion led by the trained participants.
Conclusion
This study, which displayed strong evidence of high sta-
tistical reliability of the ARTQ, is the first test of reli-
ability of this instrument in a predominantly AA sample 
with large numbers of AAs. Our analysis showed that the 
ARTQ exhibited strong evidence of high statistical reli-
ability when used in a study comprising AAs. This could 
be replicated to confirm the reliability of the ARTQ in 
other minority populations thereby laying the foundation 
for its use in these diverse populations. In future stud-
ies, the ARTQ could be used to assess the perceptions of 
other populations towards randomized trials. Such pop-
ulations include but are not limited to those with lower 
education levels, low income levels, Latino or Hispanic 
communities and subgroups of AAs (different ancestral 
background). This instrument could also be useful in 
predominantly bi-lingual or non-English speaking popu-
lations within the US who have been shown to have low 
clinical trial participation rates (Fisher and Kalbaugh 
2001).
It could be administered to potential trial participants 
to identify those whose trial perceptions indicate that 
they could benefit from participating in a clinical trials 
education program. Those who score low on the ARTQ 
may benefit the most from a cancer clinical trial educa-
tion intervention to enhance their perceptions of trials 
and to potentially increase rates of clinical trial enroll-
ment. Alternatively, the education program and the 
ARTQ could be incorporated into standard trial recruit-
ment procedures.
The ARTQ results could thus foster communication 
about trials and highlight areas where investigators could 
spend additional time describing the trial design and 
responding to questions about specific aspects or compo-
nents of the trial. Some of these aspects include informa-
tion on any previous studies, possible risks, standard of 
care, availability of insurance coverage, and availability of 
holistic health care.
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